The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 676-682

  Yorifuji, Naoki ^a   Inoue, Takuya ^a   KaIguchi, Muneta ^a   Fujiwara, Kaori ^a   Kakimoto, Kazuki ^a   Nouda, Sadaharu ^a   Okada, Toshihiko ^a   Kawakami, Ken ^a   Abe, Yosuke ^a   Takeuchi, Toshihisa ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Colorectal neoplasia glucagon like peptide 2; Diabetes; Dipeptidyl peptidase

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INTERLEUKIN 6; MESSENGER RNA; SITAGLIPTIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL TUMOR; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; GENE EXPRESSION; MALE; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OB/OB MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MOUSE MUTANT;

ANIMALS; CARCINOGENESIS; COLORECTAL NEOPLASMS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; REAL-TIME POLYMERASE CHAIN REACTION; SITAGLIPTIN PHOSPHATE;

EID: 84954271526     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4429     Document Type: Article

References (31)

1. Tsugane S and Inoue M: Insulin resistance and cancer: Epidemiological evidence. Cancer Sci 101: 1073-1079, 2010.
2. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M and Hayes RP: Diabetes in Japan: A review of disease burden and approaches to treatment. Diabetes Metab Res Rev 25: 705-716, 2009.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. K atanoda K, Matsuda T, Matsuda A, Shibata A, Nishino Y, Fujita M, Soda M, Ioka A, Sobue T and Nishimoto H: An updated report of the trends in cancer incidence and mortality in Japan. Jpn J Clin Oncol 43: 492-507, 2013.
5. H uang XF and Chen JZ: Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 10: 610-616, 2009.
6. Berster JM and Göke B: Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114: 84-98, 2008.
7. Reimer MK, Holst JJ and Ahrén B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146: 717-727, 2002.
8. Nadkarni P, Chepurny OG and Holz GG: Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci 121: 23-65, 2014.
9. Frezza EE, Wachtel MS and Chiriva-Internati M: The multiple faces of glucagon-like peptide-1-obesity, appetite, and stress: What is next? A review. Dig Dis Sci 52: 643-649, 2007.
10. Takasaki K, Takada H, Nakajima T, Ueno K, Ushiki J and Higo K : Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Eur J Pharmacol 505: 237-241, 2004.
11. Takasaki K, Nakajima T, Ueno K, Nomoto Y and Higo K: Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J Pharmacol Sci 95: 291-293, 2004.
12. D ubé PE and Brubaker PL: Frontiers in glucagon-like peptide-2: Multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293: E460-E465, 2007.
13. D rozdowski L and Thomson AB: Intestinal hormones and growth factors: Effects on the small intestine. World J Gastroenterol 15: 385-406, 2009.
14. H artmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS and Holst JJ: Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141: 4013-4020, 2000.
15. Boushey RP, Yusta B and Drucker DJ: Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacininduced murine enteritis. Am J Physiol 277: E937-E947, 1999.
16. Fujiwara K, Inoue T, Yorifuji N, Iguchi M, Sakanaka T, Narabayashi K, Kakimoto K, Nouda S, Okada T, Ishida K, et al: Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagonlike peptide-2 concentration. J Clin Biochem Nutr 56: 155-162, 2015.
17. Inoue T, Higashiyama M, Kaji I, Rudenkyy S, Higuchi K, Guth PH, Engel E, Kaunitz JD and Akiba Y: Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci 59: 1286-1295, 2014.
18. Iakoubov R, Lauffer LM, Trivedi S, Kim YI and Brubaker PL: Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 150: 4033-4043, 2009.
19. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church W B, McCaughan GW and Gorrell MD: The dipeptidyl peptidase IV family in cancer and cell biology. FE BS J 277: 1126-1144, 2010.
20. Inoue T, Murano M, Yoda Y, Kuramoto T, Kakimoto K, Ishida K, Kawakami K, Abe Y, Morita E, Murano N, et al: R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. Oncol Rep 24: 1487-1492, 2010.
21. Femia AP, Raimondi L, Maglieri G, Lodovici M, Mannucci E and Caderni G: Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 133: 2498-2503, 2013.
22. Fisher M and Knappertz V: The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Curr Med Res Opin 22: 1239-1248, 2006.
23. Berger JS, Brown DL and Becker RC: Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 121: 43-49, 2008.
24. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S and Arakawa T: Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 44: 879-888, 2009.
25. Ito Y, Sasaki M, Funaki Y, Ogasawara N, Mizuno M, Iida A, Izawa S, Masui R, Kondo Y, Tamura Y, et al: Nonsteroidal antiinflammatory drug-induced visible and invisible small intestinal injury. J Clin Biochem Nutr 53: 55-59, 2013.
26. K annen V, Garcia SB, Stopper H and Waaga-Gasser AM: Glucagon-like peptide 2 in colon carcinogenesis: Possible target for anti-cancer therapy? Pharmacol Ther 139: 87-94, 2013.
27. Sakanaka T, Inoue T, Yorifuji N, Iguchi M, Fujiwara K, Narabayashi K, Kakimoto K, Nouda S, Okada T, Kuramoto T, et al: The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol 30 (Suppl 1): S60-S65, 2015.
28. Fujiwara K, Inoue T, Yorifuji N, Iguchi M, Okada T, Kakimoto K, Nouda S, Kawakami K, Abe Y, Takeuchi T, et al: Su2022 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and Sdf-1 and does not accelerate intestinal neoplasia formation in APCMIN/+ mice fed a high fat diet. Gastroenterology 148 (Suppl 1): S-577, 2015.
29. Lin CT, Tang HY, Han YS, Liu HP, Huang SF, Chien CH, Shyy J, Chiu JJ and Chen X: Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV). Int J Biomed Sci 6: 301-309, 2010.
30. Ikeda T, Kumagai E, Iwata S and Yamakawa A: Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-in THP-1 Cells and Monocytes. PLoS One 8: e66520, 2013.
31. Reinhold D, Bank U, Bühling F, Neubert K, Mattern T, Ulmer AJ, Flad HD and Ansorge S: Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 188: 403-414, 1993.